Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 830 (ZNF830)
- Target
- ZNF830
- Molecular classification
- Transcription factor, DNA repair protein, Zinc finger protein, Component of the spliceosome, C2H2-type zinc finger protein
01
Overview
Zinc finger protein 830 (ZNF830) is a nuclear protein containing a C2H2-type zinc finger domain and coiled-coil domain, implicated in transcriptional regulation and pre-mRNA splicing as a component of the spliceosomal complex. ZNF830 acts as a key regulator of homologous recombination (HR)-mediated DNA double-strand break repair, maintaining genome integrity in proliferating cells. It is recruited to DNA damage sites in an ATR kinase-dependent manner, where it directly interacts with CtIP to facilitate DNA end resection and promote efficient repair. ZNF830 is associated with enhanced cell survival following DNA damage and mediates resistance to chemotherapeutic agents and radiotherapy in cancer. It is also required for oocyte survival and may play roles in other contexts involving DNA replication and chromosome maintenance. Overexpression or dysregulation of ZNF830 contributes to cancer progression, therapy resistance, and potentially to certain hereditary DNA repair syndromes
- Other names
- CCDC16MGC20398OMCG1Coiled-coil domain-containing protein 16orphan maintenance of genome 1hypothetical protein MGC20398
02
Mechanism of action
Not directly targeted by drugs, but modulation affects resistance/sensitivity to DNA-damaging chemotherapy or radiation by altering homologous recombination repair efficiency
03
Biological functions
DNA double-strand break repair (homologous recombination)Maintenance of genome integrityCell cycle regulationPre-mRNA splicingChromosome organizationOocyte survival
04
Disease associations
Cancer (chemoresistance, survival)Premature ovarian insufficiencyXeroderma pigmentosum (association)DNA repair disorders
05
Safety considerations
Essential function in genome stability—systemic inhibition may risk genomic instability and off-target toxicity, especially in rapidly dividing or stem/progenitor cells
06
Interacting drugs
No specific small-molecule/modulator drugs targeting ZNF830 have been reported, but its role affects sensitivity to DNA-damaging agents used in chemotherapy (e.g., IR, hydroxyurea, camptothecin, olaparib)
07
Biomarkers
ZNF830 expression (potential predictive marker for chemoresistance in cancer)SNP rs3744355 (potential association with radiotherapy adverse skin reactions in breast cancer)
Beyond the preview
Go deeper on Zinc finger protein 830 (ZNF830).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 830 (ZNF830).